Terminated/Withdrawn
Sponsor ID
20160445

Study Evaluating AMG 424 in Subjects with Multiple Myeloma

Sponsor ID
20160445
Clinicaltrials.gov ID
NCT03445663
EUCTIS ID
N/A
EudraCT ID
N/A

Study Details

A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.

Additional Study Details

Phase
Phase 1
Product
AMG 424
Type
Interventional
Masking
None (Open Label)
Enrollment
27
Additional Study Details

Protocol Summary

Primary Outcome Measures

Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0

Timeframe: 12 Months

Subject incidence of dose limiting toxicities (DLTs)

Timeframe: 28 Days

Secondary Outcome Measures

Anti-tumor activity

Timeframe: 48 Months

Duration of Response

Timeframe: 48 Months

Maximum concentration (Cmax) of AMG 424

Timeframe: 12 Weeks

Minimum concentration (Cmin) of AMG 424

Timeframe: 12 Weeks

Time of maximum concentration (Tmax) of AMG 424

Timeframe: 12 Weeks

Area under the concentration-time curve (AUC) of AMG 424

Timeframe: 12 Weeks

Time to progression

Timeframe: 48 Months

Progression-Free Survival

Timeframe: 48 Months

Overall Survival

Timeframe: 48 Months

Locations

Location
Status
Contact Us
Location
Research Site
Fitzroy, VIC, VIC, Australia, 3065
Status
Recruiting
Location
Research Site
Winston-Salem, NC, United States, 27157
Status
Recruiting
Location
Research Site
Camperdown, NSW, Australia, 2050
Status
Recruiting
Location
Research Site
Charlotte, NC, United States, 28204
Status
Recruiting
Location
Research Site
Milwaukee, WI, United States, 53226
Status
Recruiting
Location
Research Site
Seattle, WA, United States, 98104
Status
Recruiting
Showing {first} - {last} of {total} Results